{"schema_version":"secwatch.filing_event.v1","accession":"0001549084-23-000018","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.344590+00:00","generated_at":"2026-06-16T08:54:15.069301+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M","bullets":["Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.","Net loss of $4.4M ($0.33 per share) vs. $4.6M ($0.36 per share) in Q1 2022.","Booked 23 EksoHealth devices in Q1; cash position $16.3M at March 31, 2023.","Sales & marketing spend rose to $2.1M from $1.6M, reflecting HMC acquisition costs.","CEO cites multi-unit orders with large network operators and Indego product line contributions."],"urls":{"canonical":"https://secwatch.observer/filing/0001549084-23-000018","json":"https://secwatch.observer/filing/0001549084-23-000018.json","markdown":"https://secwatch.observer/filing/0001549084-23-000018.md","text":"https://secwatch.observer/filing/0001549084-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/0001549084-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/ekso-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:54:15.069301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f410b8ba1f22d7f4ba0ebbb716a547c3f5770374","claim":"EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2023 results: revenue $4.1 million, net income $4.4 million, EPS $0.33 per basic and diluted share.","evidence_excerpt":"for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments • Achieved record revenues of $4.1 million in the first quarter of 2023, up 61% from the first quarter of 2022 • Delivered products across continuum of care following the addition of the Indego ® product line • Booked a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/0001549084-23-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"$4.1 million"},{"label":"Net income","value":"$4.4 million"},{"label":"EPS","value":"$0.33 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}